This Fund Bought $63 Million of Chemours Stock Even as Shares Sit 80% Below 2017 Highs

Cooper Creek Partners initiated a new position in The Chemours Company in Q3, acquiring nearly 4 million shares worth $63.1 million as of Sept. 30, representing 1.9% of the fund’s 13F reportable assets; the fund reported $3.3 billion in U.S. equity holdings across 88 positions. Chemours, trading at $12.79 (down ~41% YTD), reported Q3 revenue of roughly $1.5 billion and $60 million in net income, with TTM revenue of $5.8 billion and a TTM net loss of $320 million; management said results exceeded expectations as Opteon refrigerants offset weakness elsewhere. The trade signals institutional confidence in a depressed chemical name amid operational stabilization, though leverage and cyclical end markets warrant caution for investors.

Analysis

Market structure: Cooper Creek’s $63M starter stake in CC (1.9% of its 13F AUM) signals an institutional view that Chemours’ Opteon refrigerants (higher-margin, HFO/HFOx franchise) can offset weakness in TiO2; direct winners are refrigerant/advanced materials channels and suppliers to HVAC/automotive, while pure-play TiO2 peers (e.g., TRONOX/TROX) and cyclical coatings suppliers look vulnerable if demand stays soft. Pricing power is bifurcated — Opteon gives Chemours idiosyncratic pricing leverage while TiO2 remains volume- and capacity-sensitive; expect split P/L dynamics over the next 2–6 quarters. Cross-asset: a visible turnaround could tighten Chemours’ CDS and HY spreads (watch 5y CDS), lift equity implied vols (short-term), and modestly reduce spot TiO2 inventory-driven volatility in commodities markets.

Risk assessment: Tail risks include a regulatory/legal PFAS-like settlement (> $500M) or a major plant outage that erodes cash flow and breaches debt covenants; assign low-probability/high-impact likelihood over 12–24 months but material if realized. Immediate (days) reaction risk is headline-driven; short-term (weeks–months) depends on Q4 guidance and Opteon sales; long-term (quarters–years) hinges on Net Debt/EBITDA trajectory (target <3.0x for safety). Hidden dependencies: insurance recoveries, pension liabilities, cyclical OEM demand and raw titanium feedstock pricing can flip margins quickly. Key catalysts: Q4 EBITDA beats, guidance raise, or regulatory clarity within 90–180 days.

Trade implications: Primary direct play is a sized long in CC (2–3% portfolio) with structured downside protection rather than naked exposure; use protective puts or collars expiring 6–12 months out. Relative-value: long CC vs short TRONOX (TROX) on expectation that refrigerants outperform pure TiO2 if global coatings demand stays weak; pair to be rebalanced monthly and closed on relative performance divergence >15% in 3–6 months. Options: buy Jan 2026 puts for defined-risk or sell covered calls to harvest yield if holding equity. Sector tilt: overweight specialty chemicals and refrigerant-exposed names, underweight bulk pigments until capacity rationalization confirmed.

Contrarian angles: The market likely over-penalizes CC for legacy liabilities while underweighting Opteon’s cash flow resilience — consensus misses the mid-cycle margin decomposition where refrigerants can drive consolidated EBITDA recovery. The 41% YTD decline and negative trailing net income create an asymmetric payoff if management converts operational stabilization into FCF growth; similar turnarounds (select specialty chemical restructurings) recovered 2x–3x over 12–24 months once leverage fell below ~3x. Unintended consequence: a coordinated institutional build (other funds following Cooper Creek) could trigger a short-squeeze; conversely, a surprise regulatory hit would reset valuations materially.

Key Decisions for Investors

• Establish a tactical long position in CC equal to 2–3% of portfolio size if entry price is ≤ $14; scale to 4–6% only on confirmed sequential EBITDA improvement or price ≤ $11.00. Hedge immediately with 9–12 month protective puts (example: buy Jan 2026 $10 puts if entry ≈ $12.50) to limit downside to ~20%.
• Implement a pair trade: long CC (equal-dollar) vs short TRONOX (TROX) for 1–2% each, horizon 3–6 months; unwind if relative performance gap exceeds 15% or if CC issues new negative guidance. Rebalance monthly.
• If owning CC outright, sell 1–3 month covered calls at ~+12–18% OTM to harvest income until a clear turnaround (defined as two consecutive quarters of positive FCF and Net Debt/EBITDA <3.0x) — cap upside but receive premium.
• Exit or materially reduce exposure if any of the following occur: (a) management reports two consecutive quarters of negative operating cash flow, (b) Net Debt/EBITDA >4.0x on reported numbers, or (c) an announced regulatory/legal charge >$500M. Monitor EPA/PFAS litigation developments and Q4 earnings within next 90 days as primary triggers.